Key statistics
On Wednesday, SAB Biotherapeutics Inc (SABS:NAQ) closed at 4.18, -36.67% below its 52-week high of 6.60, set on Jul 21, 2025.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 4.20 |
|---|---|
| High | 4.30 |
| Low | 3.94 |
| Bid | 3.94 |
| Offer | 4.38 |
| Previous close | 4.18 |
| Average volume | 328.25k |
|---|---|
| Shares outstanding | 47.61m |
| Free float | 41.72m |
| P/E (TTM) | -- |
| Market cap | 199.00m USD |
| EPS (TTM) | -2.81 USD |
Data delayed at least 15 minutes, as of Feb 11 2026 21:00 GMT.
More ▼
Announcements
- SAB BIO to Participate in Upcoming Investor Conferences
- SAB BIO Strengthens Board of Directors with Appointment of New Chair and New Director
- SAB BIO to Present at the 44th Annual J.P. Morgan Healthcare Conference
- First Patient Dosed in SAB BIO’s SAFEGUARD Clinical Trial of SAB-142 for the Treatment of Stage 3 T1D
- SAB BIO Announces Positive Confirmatory Clinical Results from the Phase 1 Study of SAB-142 in Development for the Treatment of Stage 3 T1D
- SAB BIO to Present Data Showcasing Progress in the Development of SAB-142 at the Asian Conference on Innovative Therapies for Diabetes Management
- SAB BIO Reports Third Quarter Financial Results and Recent Business Highlights
- SAB BIO to Present Data at the International Society for Pediatric and Adolescent Diabetes Annual Conference Showcasing Progress in the Development of SAB-142
- SAB BIO to Participate in Upcoming Investor Conferences
- SAB BIO Highlights Data in Multiple Presentations at EASD
More ▼
